| [1] |
Mcllwain CC, Townsend DM, Tew KD. Glutathione Stransferase polymorphisms: cancer incidence and therapy[J].Oncogene,2006,25(11): 1639-1648.
|
| [2] |
Sau A, Pellizzari Tregno F, Valentino F, et al. Glutathione transferases and development of new principles to overcome drug resistance[J]. Arch Biochem Biophys,2010,500(2): 116-122.
|
| [3] |
Arai T, Miyoshi Y, Kim SJ, et al. Association of GST P1 expression with resistance to docetaxel and paclitaxel in human breast cancers[J]. Eur J Surg Oncol,2008,34(7): 734-738.
|
| [4] |
Tew KD. Glutathione-associated enzymes in anticancer drug resistance[J]. Cancer Res,1994,54(16): 4313-4320.
|
| [5] |
Hayes JD,McLellan LI. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defence against oxidative stress[J]. Free Radic Res,1999,31(4): 273-300.
|
| [6] |
Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences[J]. Pharmacology, 2000,61(3): 154-166.
|
| [7] |
Pemble SE, Wardle AF, Taylor JB. Glutathione S-transferase class Kappa: characterization by the cloning of rat mitochondrial GST and identification of a human homologue[J]. Biochem J,1996,319 (Pt 3): 749-754.
|
| [8] |
Jakobsson PJ, Morgensterm R, Mancini J, et al. Common structural features of MAPEG -- a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism[J]. Protein Sci, 1999,8(3): 689-692.
|
| [9] |
Strange RC, Spiteri MA, Ramachandran S, et al. Glutathione-S-transferase family of enzymes[J]. Mutat Res,2001,482(1/2): 21-26.
|
| [10] |
Ji X, Blaszczyk J, Xiao B, et al. Structure and function of residue 104 and water molecules in the xenobiotic substratebinding site in human glutathione S-transferase P1-1 [J].Biochemistry,1999,38(32): 10 231-10 238.
|
| [11] |
Black SM, Beggs JD, Hayes JD, et al. Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil[J]. Biochem J,1990,268(2): 309-315.
|
| [12] |
Horton JK, Roy G, Piper JT, et al. Characterization of a chlorambucil-resistant human ovarian carcinoma cell line overexpressing glutathione S-transferase mu [ J]. Biochem Pharmacol,1999,58(4): 693-702.
|
| [13] |
Berhane K, Mannervik B. Inactivation of the genotoxic aldehyde acrolein by human glutathione transferases of classes alpha, mu, and pi[J]. Mol Pharmacol,1990,37(2): 251-254.
|
| [14] |
Dirven HA, van Ommen B, van Bladeren PJ. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases[J]. Chem Res Toxicol,1996,9(2): 351-360.
|
| [15] |
Dulik DM, Fenselau C, Hilton J. Characterization of melphalan-glutathione adducts whose formation is catalyzed by glutathione transferases[J]. Biochem Pharmacol,1986,35(19): 3405-3409.
|
| [16] |
Smith MT, Evans CG, Doane-Setzer P, et al. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells[J]. Cancer Res,1989,49(10): 2621-2625.
|
| [17] |
Ishikawa T, Ali-Osman F. Glutathione-associated cisdiamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance[J]. J Biol Chem,1993,268(27): 20116-20125.
|
| [18] |
Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione Stransferases[J]. Cancer Res,1996,56(16): 3678-3681.
|
| [19] |
Dirven HA, Megens L, Oudshoorn MJ, et al. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases [J]. Chem Res Toxicol,1995,8(7): 979-986.
|
| [20] |
Blanz J, Mewes K, Ehninger G, et al. Evidence for oxidative activation of mitoxantrone in human, pig, and rat[J]. Drug Metab Dispos,1991,19(5): 871-880.
|
| [21] |
Wolf CR, Macpherson JS, Smyth JF. Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases[J]. Biochem Pharmacol,1986,35(9): 1577-1581.
|
| [22] |
Batist G, Tulpule A, Sinha BK, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells[J]. J Biol Chem,1986,261(33): 15544-15549.
|
| [23] |
Cole SP, Downes HF, Mirski SE, et al. Alterations in glutathione and glutathione-related enzymes in a multidrugresistant small cell lung cancer cell line[J]. Mol Pharmacol,1990,37(2): 192-197.
|
| [24] |
Berhane K, Hao XY, Egyházi S, et al. Contribution of glutathione transferase M3-3 to 1, 3-bis (2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line[J]. Cancer Res,1993,53(18): 4257-4261.
|
| [25] |
Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione[J]. Cancer Res,1994,54(23): 6215-6220.
|
| [26] |
Schecter RL, Woo A, Duong M, et al. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model[J]. Cancer Res,1991,51(5): 1434-1442.
|
| [27] |
Sargent JM, Williamson C, Hall AG, et al. Evidence for the involvement of the glutathione pathway in drug resistance in AML[J]. Adv Exp Med Biol,1999,457: 205-209.
|
| [28] |
Sharma A, Patrick B,Li J, et al. Glutathione S-transferases as antioxidant enzymes: small cell lung cancer (H69) cells transfected with hGSTA1 resist doxorubicin-induced apoptosis[J].Arch Biochem Biophys,2006,452(2): 165-173.
|
| [29] |
Ban N, Takahashi Y, Takayama T, et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide[J]. Cancer Res,1996,56(15): 3577-3582.
|
| [30] |
Berhane K, Hao XY, Christensson B, et al. The expression of glutathione transferase isoenzymes in human malignant lymphoma biopsies[J]. Acta Oncol,1995,34(1): 35-41.
|
| [31] |
Lewis AD, Hayes JD, Wolf CR. Glutathione and glutathionedependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects[J]. Carcinogenesis,1988,9(7): 1283-1287.
|
| [32] |
Howells RE, Holland T, Dhar KK, et al. Glutathione Stransferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival[J]. Int J Gynecol Cancer,2001,11(2): 107-112.
|
| [33] |
Oguztuzun S,Abu-Hijleh A,Coban T,et al. GST isoenzymes in matched normal and neoplastic breast tissue[J]. Neoplasma,2011,58(4): 304-310.
|
| [34] |
Ruzza P,Rosato A,Rossi CR,et al. Glutathione transferases as targets for cancer therapy[J]. Anticancer Agents Med Chem,2009,9 (7),763-767.
|
| [35] |
Seitz G, Bonin M, Fuchs J, et al. Inhibition of glutathione-Stransferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma[J]. Int J Oncol,2010,36(2): 491-500.
|
| [36] |
Hall AG, Autzen P, Cattan AR, et al. Expression of mu class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia [J]. Cancer Res,1994,54(20): 5251-5254.
|
| [37] |
Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease[J]. Nat Genet,2003,33(2): 177-182.
|
| [38] |
Oliveira AL, Rodrigues FF, Santos RE, et al. GSTT1,GSTM1,and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer[J]. Genet Mol Res,2010,9(2): 1045-1053.
|
| [39] |
Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases(GSTM1 and GSTT1) and survival after treatment for breast cancer[J]. Cancer Res,2001,61(19): 7130-7135.
|
| [40] |
Ezer R, Alonso M, Pereira E, et al. Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas[J].J Neurooncol,2002,59(2): 123-134.
|
| [41] |
Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase(TS)--novel predictors for response and survival in gastric cancer patients[J]. Br J Cancer,2006,94(2): 281-286.
|
| [42] |
Ishimoto TM,Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli[J]. Pharmacogenetics,2002,12(7): 543-553.
|
| [43] |
Pandya U, Srivastava SK, Singhal SS, et al. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil[J]. Biochem Biophys Res Commun,2000,278(1): 258-262.
|
| [44] |
Srivastava SK, Singhal SS, Hu X, et al. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa[J].Arch Biochem Biophys,1999,366(1): 89-94.
|
| [45] |
Lu D, Shi HC, Wang ZX, et al. Multidrug resistanceassociated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma[J]. Genet Mol Res,2010,9(2): 1045-1053.
|
| [46] |
Arai T,Miyoshi Y,Kim SJ,et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers[J]. Eur J Surg Oncol,2008,34(7): 734-738.
|
| [47] |
Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance[J]. Oncogene,2003,22(47): 7369-7375.
|
| [48] |
Gaudiano G, Koch TH, Lo Bello M, et al. Lack of glutathione conjugation to adriamycin in human breast cancer MCF-7/DOX cells. Inhibition of glutathione S-transferase p1-1 by glutathione conjugates from anthracyclines[J]. Biochem Pharmacol,2000, 60(12): 1915-1923.
|
| [49] |
Peters WH, Roelofs HM. Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione Stransferases[J]. Cancer Res,1992,52(7): 1886-1890.
|
| [50] |
Singhal SS, Saxena M, Ahmad H, et al. Glutathione Stransferases of human lung: characterization and evaluation of the protective role of the alpha-class isozymes against lipid peroxidation[J]. Arch Biochem Biophys,1992,299(2): 232-241.
|
| [51] |
Zhou L, Jing Y, Styblo M, et al. Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism[J]. Blood, 2005, 105(3): 1198-1203.
|
| [52] |
Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp[J]. EMBO J,1999,18(5): 1321-1334.
|
| [53] |
Yin Z, Ivanov VN, Habelhah H, et al. Glutathione Stransferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases[J]. Cancer Res,2000,60(15): 4053-4057.
|
| [54] |
Bernardini S, Bellincampi L, Ballerini S, et al. Role of GST P1-1 in mediating the effect of etoposide on human neuroblastoma cell line Sh-Sy5y[J]. J Cell Biochem, 2002,86(2): 340-347.
|
| [55] |
Cho SG, Lee YH, Park HS, et al. Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1[J]. J Biol Chem, 2001,276(16): 12749-12755.
|
| [56] |
Dorion S,Lambert H,Landry J. Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione Stransferase Mu from Ask1[J]. J Biol Chem,2002,277(34): 30792-30797.
|
| [57] |
Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK)1[J]. EMBO J,1998,17(9): 2596-2606.
|
| [58] |
Davis RJ. Signal transduction by the JNK group of MAP kinases[J]. Cell,2000,103(2): 239-252.
|
| [59] |
Ono K,Han J. The p38 signal transduction pathway: activation and function[J]. Cell Signal,2000,12(1): 1-13.
|
| [60] |
Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy[J].Drug Resist Updat,2001,4(4): 253-267.
|
| [61] |
Potapova O, Haghighi A, Bost F,et al. The Jun kinase/stressactivated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin[J]. J Biol Chem,1997,272(22): 14041-14044.
|
| [62] |
Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines[J]. Cancer Res,1988,48(13): 3622-3625.
|
| [63] |
Petrini M, Conte A, Caracciolo F, et al. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient[J]. Br J Haematol,1993,85(2): 409-410.
|
| [64] |
Tew KD, Dutta S, Schultz M. Inhibitors of glutathione Stransferases as therapeutic agents[J]. Adv Drug Deliv Rev,1997,26(2-3): 91-104.
|
| [65] |
Raza A, Galili N, Smith S, et al. Phase 1 multicenter doseescalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome[J]. Blood,2009,113(26): 6533-6540.
|
| [66] |
Morgan AS, Ciaccio PJ, Tew KD, et al. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines [J]. Cancer Chemother Pharmacol,1996,37(4): 363-370.
|
| [67] |
Federici L, Lo Sterzo C, Pezzola S, et al. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol to human glutathione stransferases[J]. Cancer Res,2009,69(20): 8025-8034.
|
| [68] |
Ascione A, Cianfriglia M, Dupuis ML, et al. The glutathione S-transferase inhibitor 6-( 7-nitro-2, 1, 3-benzoxadiazol-4-ylthio) hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells[J]. Cancer Chemother Pharmacol,2009,64(2): 419-424.
|
| [69] |
Filomeni G, Turella P, Dupuis ML, et al. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol, a specific glutathione Stransferase inhibitor, overcomes the multidrug resistance(MDR)-associated protein 1-mediated MDR in small cell lung cancer[J]. Mol Cancer Ther,2008,7(2): 371-379.
|
| [70] |
Pellizzari Tregno F, Sau A, Pezzola S, et al. In vitro and in vivo efficacy of 6-(7-nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma[J]. Eur J Cancer,2009,45(14): 2606-2617.
|